Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
复制标题
人类 IgM 和 IgG 对灭活 SARS-CoV-2 疫苗的反应
DOI：
10.1007/s11596-021-2461-8
复制
发表时间：
2021-12
影响因子：
2.4
通讯作者：
Fan XL
中科院分区：
文献类型：
--
作者：
Banga Ndzouboukou JL;Zhang YD;Lei Q;Lin XS;Yao ZJ;Fu H;Yuan LY;Fan XL
持续的COVID-19大流行需要加快测试候选疫苗的努力。为探讨疫苗诱导效应的影响因素，对未感染过COVID-19的健康人群进行了SARS-CoV-2灭活疫苗抗体反应评估。方法对2021年6月19日至2021年7月2日筛查时未发生SARS-CoV-2感染的18-60岁受试者进行纳入。所有参与者都接种了两剂灭活的SARS-CoV-2疫苗。在第二剂疫苗接种后，使用商业试剂盒检测血清IgM和IgG抗体。阳性结果定义为10 AU/mL或更高，阴性结果定义为小于10 AU/mL。本回顾性研究纳入97例infection-naïve个体（平均年龄35.6岁，男性37.1%，女性62.9%）。结果第2次灭活疫苗血清IgM抗体和IgG抗体阳性率分别为3.1%和74.2%。IgG抗体水平显著高于IgM抗体水平（P<0.0001）。第二次注射后，性别对IgM和IgG抗体反应无影响。老年人（小于或等于42岁）的平均抗igg水平显著低于年轻接受者。与第二次给药后0 ~ 20天和21 ~ 31天相比，第二次给药后bb0 ~ 42天抗体水平显著降低（P<0.05）。结论SARS-CoV-2灭活疫苗可诱导健康人群（0 ~ 18岁）产生igg抗体应答，且受年龄和二次接种后检测时间的影响。
ObjectiveThe ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. To explore the influencing factors on vaccine-induced effects, antibody responses to an inactivated SARS-CoV-2 vaccine in healthy individuals who were not previously infected by COVID-19 were assessed.MethodsAll subjects aged 18–60 years who did not have SARS-CoV-2 infection at the time of screening from June 19, 2021, to July 02, 2021, were approached for inclusion. All participants received two doses of inactivated SARS-CoV-2 vaccine. Serum IgM and IgG antibodies were detected using a commercial kit after the second dose of vaccination. A positive result was defined as 10 AU/mL or more and a negative result as less than 10 AU/mL. This retrospective study included 97 infection-naïve individuals (mean age 35.6 years; 37.1% male, 62.9% female).ResultsThe seropositive rates of IgM and IgG antibody responses elicited after the second dose of inactivated SARS-CoV-2 vaccine were 3.1% and 74.2%, respectively. IgG antibody levels were significantly higher than IgM levels (P<0.0001). Sex had no effect on IgM and IgG antibody response after the second dose. The mean anti-IgG level in older persons (⩾42 years) was significantly lower than that of younger recipients. There was a significantly lower antibody level at > 42 days compared to that at 0–20 days (P<0.05) and 21–31 days (P<0.05) after the second dose.ConclusionIgG antibody response could be induced by inactivated SARS-CoV-2 vaccine in healthy individuals (>18 years), which can be influenced by age and detection time after the second dose of vaccination.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
影响因子：
32.4
作者：
Quast I;Tarlinton D
通讯作者：
Tarlinton D
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
抗SARS-COV-2受体结合结构域的血清阳性和血清效率医疗保健工人的总抗体反应正在接受COVID-19 MRNA BNT162B2疫苗接种。
DOI：
10.3390/diagnostics11050832
发表时间：
2021-05-04
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Salvagno GL;Henry BM;di Piazza G;Pighi L;De Nitto S;Bragantini D;Gianfilippi GL;Lippi G
通讯作者：
Lippi G
DOI：
10.3390/diagnostics11030426
发表时间：
2021-03-03
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Dörschug A;Frickmann H;Schwanbeck J;Yilmaz E;Mese K;Hahn A;Groß U;Zautner AE
通讯作者：
Zautner AE